This brand name is authorized in Turkey
The drug REPLIC contains one active pharmaceutical ingredient (API):
|
1
Repaglinide
UNII 668Z8C33LU - REPAGLINIDE
|
|
Repaglinide is a short-acting oral secretagogue. Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning β-cells in the pancreatic islets. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BX02 | Repaglinide | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BX Other blood glucose lowering drugs, excl. insulins |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8697929010849, 8697929010856, 8697929010863, 8697929010870, 8697929010887, 8697929010894 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
